Biocartis, Genomic Health to Develop IVD Version of Oncotype Prostate Test

Dec 04, 2018

|

NEW YORK (GenomeWeb) – Biocartis said yesterday that it has signed a development agreement with Genomic Health to develop an in vitro diagnostic version of the Oncotype DX Genomic Prostate Score (GPS) Test.

The agreement expands on a previous partnership to develop an IVD version of Genomic Health's Oncotype DX Breast Recurrence Score test on Biocarts' Idylla platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biocartis, Genomic Health to Develop IVD Version of Oncotype Prostate Test

To read the full story....

Breaking News

Biden Administration Funds $1B for COVID-19 Testing in Indian Country

Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

NIH Awards Qorvo Biotechnologies $24.4M for Rapid SARS-CoV-2 Antigen Test

In Brief This Week: Exact Sciences, Siemens Healthineers, Seegene, Agilent Technologies, and More

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

Featured White Papers

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

NIH Funds $33M in COVID-19 Testing Projects for Safe Return of Students, Staff to School

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

Labs Craft SARS-CoV-2 Variant Genotyping Assays for Screening, Surveillance

Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

Sponsorships